The document summarizes the pharmaceutical industry in India. It provides an overview of the industry, noting that it is highly fragmented with over 20,000 registered units and is a $4.5 billion industry growing annually by 8-9%. It also profiles some of the largest pharmaceutical companies in India, including Ranbaxy, Dr. Reddy's Laboratories, and Cipla, and discusses their operations, market shares, and R&D investments. The industry is a major exporter of generic drugs and has a competitive advantage due to its skilled workforce and cost-effective production capabilities.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
This ppt gives an overview of the Indian Pharmaceutical sector. We have concentrated on 5 aspects of the sector and analysed it. The covered heads are history, business model, Marketing, Competitor analysis, Financials and Trends.
The Indian markets and financial institutions stand out as sound, stable and better
regulated in contrast to developed economies. As a result, India can continue to be an
attractive market in view of its strong and stable fundamentals and the resilience which
Indian economy has displayed so far
India is among the top six global pharmaceutical producers in the world. Indian vaccines are exported to 150 countries. India produces 40-70 per cent of the WHO demand for DPT & BCG and 90 per cent of measles vaccine. Approximately 70 per cent of the patients in developing countries receive Indian medicines through NGOs like The Clinton Foundation, Bill & Melinda Gates Foundation, Doctors without Borders, the UNCTAD etc.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
THE INDIAN GOVERNMENT HAS STARTED TO ENCOURAGE THE GROWTH OF DRUG MANUFACTURING BY INDIAN COMPANIES IN THE EARLY 1960s. AT PRESENT THERE ARE MANY NUMBER OF PHARMACEUTICAL COMPANIES IN INDIA WITH MANY NOVEL DRUG INVENTORIES
indian Pharmaceutical industry export import overviewbipindapin
Pharmaceutical Industry-EXPORT IMPORT INDIA
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices
Status of pharmaceutical industry in indiaShadab Khan
Status of Pharmaceutical Industry in India
-History
-Evolution
-Current Scenario
-Market Share
-Government Initiatives
-Top 10 Pharmaceutical Industry
-R&D Spendings
-Challenges
-Road Ahead
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Introduction Indian Pharmaceutical market, SWOT analysis, PEST Analysis, Timeline analysis of Sun Pharma, Glaxo Smith Kline, Mankind, CIPLA and Zydus Cadila.
Pharmaceutical market india a comprehensive industry analysis - Reports CornerReports Corner
"1.0 Summary
“Pharmaceutical Market: India, A Competitive Industry Analysis” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.
The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $13 billion. It is forecast to reach $50 billion by 2015 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $74 billion.
This report describes the current therapeutics that are propelling the biopharmaceutical market in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.
https://www.reportscorner.com/reports/15826/Pharmaceutical-Market:-India-A-Comprehensive-Industry-Analysis/
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
THE INDIAN GOVERNMENT HAS STARTED TO ENCOURAGE THE GROWTH OF DRUG MANUFACTURING BY INDIAN COMPANIES IN THE EARLY 1960s. AT PRESENT THERE ARE MANY NUMBER OF PHARMACEUTICAL COMPANIES IN INDIA WITH MANY NOVEL DRUG INVENTORIES
indian Pharmaceutical industry export import overviewbipindapin
Pharmaceutical Industry-EXPORT IMPORT INDIA
The pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices
Status of pharmaceutical industry in indiaShadab Khan
Status of Pharmaceutical Industry in India
-History
-Evolution
-Current Scenario
-Market Share
-Government Initiatives
-Top 10 Pharmaceutical Industry
-R&D Spendings
-Challenges
-Road Ahead
Indian pharmaceutical industry: Policies, achievements and challengesRajesh Kochhar
Indian pharmaceutical industry is a success story from a national as well as third-world perspective. India accounts for 10% of world production and ranks third in the world in terms of volume. In value terms the share is only 1.4% and the rank 14th.
his statistic underlines the important fact that India produces world-class generic drugs at a very low cost. Indian domestic pharma market, currently evaluated at $12 bn, is largely self-sufficient with patented drugs playing a minimal role.
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Internship Report on Square Pharmaceuticals Ltd.Mahfuz Tushar
The internship report primarily focuses on the Recruitment and Selection process of the
company. This report points out the existing conditions regarding employee recruitment and
selection that means find out the best personnel for the organization.
Dear Students
We can help you to write total dissertation/project report.
Our 9 step method of project writing:-
Step 1) Helping you in Selection of topic.
Step 2) Group discussion / conference call with in team of professors.
Step 3) Helping you in Preparation of Synopsis/ proposal & sent to project guide
This presentation is on research methodology for project work for undergraduate students . It consist of two part , first part speaks about the overall research methodology for research and second part is based on the guidelines issues by Goa University in the project manual for final year undergraduate students.
Present Status and Scope of Pharmaceutical industry in IndiaMadhuraNewrekar
The Indian pharmaceutical industry came into existence in 1901, when Bengal Chemical & Pharmaceutical Company started its maiden operation in Calcutta.
The next few decades saw the pharmaceutical industry moving through several phases, largely in accordance with government policies. The development, present status and scope of pharmaceutical industry in India.
Project on Production and Packaging in Pharmaceutical Industry Emcure By Nikh...Nikhil Dhawan
This is the Complete Project that I`ve Completed on 7/08/2014 and It is Now Brand New Project Report Suitable for Students doing MBA, PGDBM and Having Topics like Marketing or HR. No Ads, No Price, No Money!
You Can Contact Me for More Free Projects! Just Download the Project and Enjoy! Cheers!!
Best of Luck
Nikhil Dhawan
9018580277, 9622334428
nikdhawan@outlook.com.
contactnikhildhawan@gmail.com.
contact_nikhildhawan@gmail.com
Pharmaceutical industry
Overview of industry
The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications.
Pharmaceutical companies may deal in generic or brand medications and medical devices.
Global Players of Industry
Johnson & Johnson
With nearly US$71.89 billion more in revenue, Johnson & Johnson is by far the world’s largest pharmaceutical company based on revenue.
Pfizer (US$52.82bn)
In second place, American biopharmaceutical company Pfizer has moved up two places from last year. The company focuses on a wide range of therapy areas including oncology, neuroscience, metabolic diseases and rare disease, as well as developing vaccines.
Roche (US$50.11bn)
In the top three pharmaceutical companies of 2017 is another Swiss-based pharma, Roche. The company develops drugs and diagnostic instruments and has a presence in Europe, North America, South America and Asia.
India Orthopedic Devices Market: Unlocking Growth Secrets, Trends and Develop...Kumar Satyam
According to TechSci Research report, “India Orthopedic Devices Market -Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030”, the India Orthopedic Devices Market stood at USD 1,280.54 Million in 2024 and is anticipated to grow with a CAGR of 7.84% in the forecast period, 2026-2030F. The India Orthopedic Devices Market is being driven by several factors. The most prominent ones include an increase in the elderly population, who are more prone to orthopedic conditions such as osteoporosis and arthritis. Moreover, the rise in sports injuries and road accidents are also contributing to the demand for orthopedic devices. Advances in technology and the introduction of innovative implants and prosthetics have further propelled the market growth. Additionally, government initiatives aimed at improving healthcare infrastructure and the increasing prevalence of lifestyle diseases have led to an upward trend in orthopedic surgeries, thereby fueling the market demand for these devices.
What are the main advantages of using HR recruiter services.pdfHumanResourceDimensi1
HR recruiter services offer top talents to companies according to their specific needs. They handle all recruitment tasks from job posting to onboarding and help companies concentrate on their business growth. With their expertise and years of experience, they streamline the hiring process and save time and resources for the company.
Personal Brand Statement:
As an Army veteran dedicated to lifelong learning, I bring a disciplined, strategic mindset to my pursuits. I am constantly expanding my knowledge to innovate and lead effectively. My journey is driven by a commitment to excellence, and to make a meaningful impact in the world.
Accpac to QuickBooks Conversion Navigating the Transition with Online Account...PaulBryant58
This article provides a comprehensive guide on how to
effectively manage the convert Accpac to QuickBooks , with a particular focus on utilizing online accounting services to streamline the process.
The world of search engine optimization (SEO) is buzzing with discussions after Google confirmed that around 2,500 leaked internal documents related to its Search feature are indeed authentic. The revelation has sparked significant concerns within the SEO community. The leaked documents were initially reported by SEO experts Rand Fishkin and Mike King, igniting widespread analysis and discourse. For More Info:- https://news.arihantwebtech.com/search-disrupted-googles-leaked-documents-rock-the-seo-world/
What is the TDS Return Filing Due Date for FY 2024-25.pdfseoforlegalpillers
It is crucial for the taxpayers to understand about the TDS Return Filing Due Date, so that they can fulfill your TDS obligations efficiently. Taxpayers can avoid penalties by sticking to the deadlines and by accurate filing of TDS. Timely filing of TDS will make sure about the availability of tax credits. You can also seek the professional guidance of experts like Legal Pillers for timely filing of the TDS Return.
3.0 Project 2_ Developing My Brand Identity Kit.pptxtanyjahb
A personal brand exploration presentation summarizes an individual's unique qualities and goals, covering strengths, values, passions, and target audience. It helps individuals understand what makes them stand out, their desired image, and how they aim to achieve it.
Attending a job Interview for B1 and B2 Englsih learnersErika906060
It is a sample of an interview for a business english class for pre-intermediate and intermediate english students with emphasis on the speking ability.
Taurus Zodiac Sign_ Personality Traits and Sign Dates.pptxmy Pandit
Explore the world of the Taurus zodiac sign. Learn about their stability, determination, and appreciation for beauty. Discover how Taureans' grounded nature and hardworking mindset define their unique personality.
[Note: This is a partial preview. To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
Sustainability has become an increasingly critical topic as the world recognizes the need to protect our planet and its resources for future generations. Sustainability means meeting our current needs without compromising the ability of future generations to meet theirs. It involves long-term planning and consideration of the consequences of our actions. The goal is to create strategies that ensure the long-term viability of People, Planet, and Profit.
Leading companies such as Nike, Toyota, and Siemens are prioritizing sustainable innovation in their business models, setting an example for others to follow. In this Sustainability training presentation, you will learn key concepts, principles, and practices of sustainability applicable across industries. This training aims to create awareness and educate employees, senior executives, consultants, and other key stakeholders, including investors, policymakers, and supply chain partners, on the importance and implementation of sustainability.
LEARNING OBJECTIVES
1. Develop a comprehensive understanding of the fundamental principles and concepts that form the foundation of sustainability within corporate environments.
2. Explore the sustainability implementation model, focusing on effective measures and reporting strategies to track and communicate sustainability efforts.
3. Identify and define best practices and critical success factors essential for achieving sustainability goals within organizations.
CONTENTS
1. Introduction and Key Concepts of Sustainability
2. Principles and Practices of Sustainability
3. Measures and Reporting in Sustainability
4. Sustainability Implementation & Best Practices
To download the complete presentation, visit: https://www.oeconsulting.com.sg/training-presentations
Enterprise Excellence is Inclusive Excellence.pdfKaiNexus
Enterprise excellence and inclusive excellence are closely linked, and real-world challenges have shown that both are essential to the success of any organization. To achieve enterprise excellence, organizations must focus on improving their operations and processes while creating an inclusive environment that engages everyone. In this interactive session, the facilitator will highlight commonly established business practices and how they limit our ability to engage everyone every day. More importantly, though, participants will likely gain increased awareness of what we can do differently to maximize enterprise excellence through deliberate inclusion.
What is Enterprise Excellence?
Enterprise Excellence is a holistic approach that's aimed at achieving world-class performance across all aspects of the organization.
What might I learn?
A way to engage all in creating Inclusive Excellence. Lessons from the US military and their parallels to the story of Harry Potter. How belt systems and CI teams can destroy inclusive practices. How leadership language invites people to the party. There are three things leaders can do to engage everyone every day: maximizing psychological safety to create environments where folks learn, contribute, and challenge the status quo.
Who might benefit? Anyone and everyone leading folks from the shop floor to top floor.
Dr. William Harvey is a seasoned Operations Leader with extensive experience in chemical processing, manufacturing, and operations management. At Michelman, he currently oversees multiple sites, leading teams in strategic planning and coaching/practicing continuous improvement. William is set to start his eighth year of teaching at the University of Cincinnati where he teaches marketing, finance, and management. William holds various certifications in change management, quality, leadership, operational excellence, team building, and DiSC, among others.
Digital Transformation in PLM - WHAT and HOW - for distribution.pdf
Brief Report on the Indian Pharmaceutical Industry - 2011
1. A BRIEF REPORT PHARMACEUTICAL INDUSTRY IN INDIA
January, 2011
2. 1. OVERVIEW OF PHARMACUETICAL INDUSTRY
1.1. An Introduction
The Indian pharmaceutical industry currently tops the chart amongst India's science-based
industries with wide ranging capabilities in the complex field of drug manufacture and
technology. A highly organized sector, the Indian pharmaceutical industry is estimated to be
worth $ 4.5 billion, growing at about 8 to 9 percent annually. It ranks very high amongst all the
third world countries, in terms of technology, quality and the vast range of medicines that are
manufactured. It ranges from simple headache pills to sophisticated antibiotics and complex
cardiac compounds, almost every type of medicine is now made in the Indian pharmaceutical
industry.
The Indian pharmaceutical sector is highly fragmented with more than 20,000 registered units. It
has expanded drastically in the last two decades. The Pharmaceutical and Chemical industry in
India is an extremely fragmented market with severe price competition and government price
control. The Pharmaceutical industry in India meets around 70% of the country's demand for
bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals
and injectibles. There are approximately 250 large units and about 8000 Small Scale Units, which
form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units).
The Government has also played a vital role in the development of the India Software Industry.
In 1986, the Indian government announced a new software policy which was designed to serve
as a catalyst for the software industry. This was followed in 1988 with the World Market Policy
and the establishment of the Software Technology Parks of India (STP) scheme. In addition, to
attract foreign direct investment, the Indian Government permitted foreign equity of up to 100
percent and duty free import on all inputs and products.
1.2 Current Scenario
India's pharmaceutical industry is now the third largest in the world in terms of volume and
stands 14th in terms of value. According to data published by the Department of
Pharmaceuticals, Ministry of Chemicals and Fertilizers, the total turnover of India's
pharmaceuticals industry between September 2008 and September 2009 was US$ 21.04 billion.
Of this the domestic market was worth US$ 12.26 billion.
The Indian pharmaceuticals market is expected to reach US$ 55 billion in 2020 from US$ 12.6
billion in 2009. The market has the further potential to reach US$ 70 billion by 2020 in an
aggressive growth scenario.
Moreover, the increasing population of the higher-income group in the country, will open a
potential US$ 8 billion market for multinational companies selling costly drugs by 2015. Besides,
the domestic pharma market is estimated to touch US$ 20 billion by 2015, making India a
lucrative destination for clinical trials for global giants.
Further estimates the healthcare market in India to reach US$ 31.59 billion by 2020.
3. 12.1. Diagnostics Outsourcing/Clinical Trials
The Indian diagnostic services are projected to grow at a CAGR of more than 20 per cent during
2010-2012.
Some of the major Indian pharmaceutical firms, including Sun Pharma, Cadilla Healthcare and
Piramal Life Sciences, had applied for conducting clinical trials on at least 12 new drugs in 2010,
indicating a growing interest in new drug discovery research.
1.2.2 Generics
India tops the world in exporting generic medicines worth US$ 11 billion and currently, the
Indian pharmaceutical industry is one of the world's largest and most developed.
Moreover, the Indian generic drug market to grow at a CAGR of around 17 per cent between
2010-11 and 2012-13. Union Minister of Commerce and Industry and Minister for Trade and
Industry, Singapore, have signed a 'Special Scheme for Registration of Generic Medicinal
Products from India' in May 2010, which seeks to fast-track the registration process for Indian
generic medicines in Singapore.
1.3 Advantage India
The Indian Pharmaceutical Industry, particularly, has been the front runner in a wide range of
specialties involving complex drugs' manufacture, development and technology. With the
advantage of being a highly organised sector, the pharmaceutical companies in India are growing
at the rate of $ 4.5 billion, registering further growth of 8 - 9 % annually.
More than 20,000 registered units are fragmented across the country and reports say that 250
leading Indian pharmaceutical companies control 70% of the market share with stark price
competition and government price regulations.
Competent workforce: India has a pool of personnel with high managerial and technical competence
as also skilled workforce. It has an educated work force and English is commonly used.
Professional services are easily available.
Cost-effective chemical synthesis: Its track record of development, particularly in the area of improved
cost-beneficial chemical synthesis for various drug molecules is excellent. It provides a wide
variety of bulk drugs and exports sophisticated bulk drugs.
Legal & Financial Framework: India has a 53 year old democracy and hence has a solid legal
framework and strong financial markets. There is already an established international industry
and business community.
Information & Technology: It has a good network of world-class educational institutions and
established strengths in Information Technology.
Globalisation: The country is committed to a free market economy and globalization. Above all, it
has a 70 million middle class market, which is continuously growing.
4. Consolidation: For the first time in many years, the international pharmaceutical industry is finding
great opportunities in India. The process of consolidation, which has become a generalized
phenomenon in the world pharmaceutical industry, has started taking place in India.
5. 2 MAJOR PHARMACEUTICAL COMPANIES IN INDIA
Some of the leading Indian players by sales (US$ million)
Company name Sales in US$ million Year End
Cipla 1,033.46 March 2009
Ranbaxy Lab 951.03 December 2008
Dr Reddy's Labs 866.44 March 2009
Sun Pharma 805.51 March 2009
LupinLtd 603.99 March 2009
Aurobindo Pharma 582.27 March 2009
Piramal Health 483.10 March 2009
Cadila Health 354.02 March 2009
Matrix Labs 310.06 March 2009
Wockhardt 309.68 December 2009
2.1 Ranbaxy
Ranbaxy is among the predominant pharmaceutical companies in India and was founded in 1961.
Ranbaxy is a research based pharma giant and became a public limited company in 1973.
Ranbaxy was recently ranked among the top 10 international pharmaceutical companies in the
world have presence across 49 countries.
Ranbaxy is also reputed for its 11 state-of-the-art manufacturing facilities in countries like China,
India, Brazil, South Africa, and Nigeria. The company has also won several awards and
recognitions for its pioneering initiatives in the developing markets of the world. Ranbaxy is also
a member of the Indian Pharmaceutical Alliance and Organization of Pharmaceutical Producers
of India. In the present scenario Ranbaxy commands more than 5% share of the Indian
pharmaceutical market. Ranbaxy’s product portfolio is diverse and includes drugs that cater to
nutrition, infectious diseases, gastro-enteritis, pain management, cardiovascular ailments,
dermatology, and central nervous system related ailments.
Ranbaxy’s operations in India are designed under as many as 9 SBUs which take care of the
various categories of medicines and drugs that are manufactured by Ranbaxy. The company is
especially well-known for having the highest research and development (R&D) budget among
pharma companies in the world which is as high as US$ 100 million.
Ranbaxy India operations are handled by 2,500 employees and the company’s market share in
India is worth around US$6 billion.
2.2 Dr. Reddy's Laboratories
Dr. Reddy's Laboratorie is one of the popular pharmaceutical companies with base in more than
100 countries. The medicines of Dr. Reddy's Laboratories Limited are easily available all across
the globe.
6. Dr. Reddy's Pharmaceutical Company is very much customer friendly. It takes care of the fact
that maximum people get benefited by the products of this pharmaceutical company. It
commercialized various treatments so as to provide high tech treatment to the masses. It tries to
meet the medical needs of the people.
Though Dr. Reddy's Laboratories is located in various parts of the world, it has its headquarters
in India. The subsidiaries of this company are found at various countries like US, Germany, UK,
Russia and Brazil. 16 countries have the representative offices of Dr. Reddy's Laboratories
Limited. 21 countries have third party distribution.
2.3 Cipla
Cipla was founded by Khwaja Abdul Hamied in 1935 and was known as The Chemical,
Industrial and Pharmaceutical Laboratories, though it is better known by the acronym Cipla
today. Cipla was registered in August, 1935 as a public limited enterprise and it began with an
authorized capital of Rs. 6 lakh.
Though set up in 1935, it was only in 1937 that Cipla began manufacturing and marketing its
pharmaceutical products. Today, the company has its facilities spread across several locations
across India such as Mumbai, Goa, Patalganga, Kurkumbh, Bangalore, and Vikhroli.
Apart from its strong presence in the Indian market, Cipla also has an extensive export market
and regularly exports to more than 150 countries in regions such as North America, South
American, Asia, Europe, Middle East, Australia, and Africa. For the year ended 31st March,
2007 Cipla’s exports were worth approximately Rs. 17,500 million. Cipla is also considerably
well-known for its technological innovation and processes for which the company received
know-how loyalties to the tune of Rs. 750 million during 2006-07.
2.4 Sun Pharmaceuticals
Sun Pharmaceuticals was set up in 1983 and the company started off with only 5 products to
cure psychiatric illness. Sun Pharma is known worldwide as the manufacture of specialty Active
Pharmaceuticals Ingredients and formulations.
However, the company is also concerned with chronic treatments such as cardiology, psychiatry,
neurology, gastroenterology, diabetology, and respiratory ailments. Active Pharmaceuticals
Ingredients (API) include peptides, steroids, hormones, and anti-cancer drugs and their quality is
internationally approved. The international offices of Sun Pharmaceuticals Industries Ltd. are
located in British Virgin Islands, Russia, and Bangladesh. In India, the offices are in Vapi,
Silvassa, Panoli, Ahmednagar, and Chennai.
There are 3 major group companies of Sun Pharmaceuticals Industries are:
• Caraco Pharmaceuticals Laboratories (based in Detroit, Michigan)
• Sun Pharmaceuticals Industries Inc. (Michigan)
• Sun Pharmaceuticals (Bangladesh)
7. 2.5 Aurobindo Pharma
Aurobindo Pharma, an India-based private pharmaceutical company having presence around the
world. Aurobindo Pharma was set up in the year 1986 and started its operations in 1988-89 in
Pondicherry, India. Now, the company is headquartered at Hyderabad, India.
Aurobindo Pharma is one of the most respected generic pharmaceuticals and active
pharmaceutical ingredients (API) manufacturing company of the world. Aurobindo Pharma
operates in over 100 countries across the world. Further, the pharmaceutical major markets over
180 APIs and 250 formulations throughout these destinations. This Indian pharmaceutical major
has filed over 110 DMFs and 90 ANDAs for the USA market. So far, Aurobindo has received
45 ANDA approvals (both final and tentative) from USA alone.
Aurobindo Pharma products cover segments like –
• Antibiotics,
• Anti-Retro Virals
• CVS
• CNS
• Gastroenterologicals
• Anti-Allergics
8. 3 GOVERNMENT INITIATIVES AND INVESTMENT
3.1 Government Initiative
100 per cent foreign direct investment (FDI) is allowed under the automatic route in the drugs
and pharmaceuticals sector including those involving use of recombinant technology. (DIPP)
The Government plans to set up a US$ 639.56 million venture capital (VC) fund to give a boost
to drug discovery and strengthen the pharma infrastructure in the country.
The Government had issued an expression of interest (EoI) for technical and financial bids for
the selection of a global level consultant (GLC) for the preparation of a detailed project report
(DPR) in order to develop India as a drug discovery and pharma innovation hub by 2020. The
Drugs and Pharmaceuticals Manufacturers Association has received an in-principle approval for
its proposed special economic zone (SEZ) for pharmaceuticals, bulk drugs, active
pharmaceutical ingredients (APIs) and formulations to be located at Nakkapalli mandal in
Visakhapatnam district.
The Department of Pharmaceuticals has prepared a "Pharma Vision 2020" for making India one
of the leading destinations for end-to-end drug discovery and innovation and for that purpose
provides requisite support by way of world class infrastructure, internationally competitive
scientific manpower for pharma research and development (R&D), venture fund for research in
the public and private domain and such other measures.
The government plans to open 3,000 Jan Aushadhi stores, which sell unbranded generic drugs at
heavy discounts to branded drugs, in the next two years.
3.2 Investment
The healthcare sector has attracted growing investor support in 2010 with nearly a tenth of the
total private equity funding going to this sector. In the third quarter the calendar year 2010, a
total of US$ 2,047 million was invested across 88 deals, of which 9 per cent were healthcare
deals.
The pharma, healthcare and biotech sector witnessed five merger and acquisition transactions
(M&A) worth US$ 250 million.
The drugs and pharmaceuticals sector has attracted FDI worth US$ 1,825.43 million between
April 2000 and September 2010.
Some of the major investment developments in the sector include:
• Hyderabad-based Natco Pharma plans to raise US$ 22.22 million to fund its expansion plans
and research activities.
• Private equity major Sequoia Capital has made its first investment in the pharmaceutical
sector in the country by investing US$ 15.86 million into Celon Labs, which will use the
funds to double its manufacturing facility.
9. • Belgium based Helvoet Pharma, part of the Daetwyler Group is setting up its first greenfield
production facility in Khandala Industrial Area, phase I (SEZ), on Pune- Bangalore Highway,
near Pune. The company has invested US$ 26.56 million for the plant.
• Swiss Pharma major Lonza AG, would invest around US$ 55.33 million through its Indian
subsidiary in a phased manner in Genome Valley project, Hyderabad, said Stefan Borgas,
CEO, Lonza.
• Chennai-based Bafna Pharmaceuticals plans to raise around US$ 4.43 million for its future
expansion by issuance of warrants and shares.
• Hyderabad Menzies Air Cargo Private Limited, a joint venture between GMR Hyderabad
International Airport Limited (GHIAL) and Menzies Aviation, has launched India's first
airport-based pharma zone, dedicated pharmaceutical cargo storage and handling facility, at
Hyderabad. The project involved an investment of US$ 1.22 million.
10. 4 CHALLENGES & FUTURE GROWTH
4.1 Challenges
Over the past decade, pharmaceutical companies have entered a difficult period where
shareholders, the market and regulators have created significant pressures for change within the
industry. The core issues for most of drug companies are declining productivity of in-house R &
D, patent expiration of number of block buster drugs, increasing legal and regulatory concern,
and pricing issue. As a result larger pharmaceutical companies are shifting to new business
model with greater outsourcing of discovery services, clinical research and manufacturing.
Current global financial conditions and the threat of a broad recession accelerated the timetable
for implementing transformational changes in global organizations, as the industry confronts
lower corporate stock prices and an increasingly cost-averse customer. Leaders of the largest
global pharmaceutical companies recognize the need for transformational change in their
organizations, but will need to move swiftly to ensure sustained growth.
Transformations in the business model of larger pharmaceutical industry spell more
opportunities for Indian pharmaceutical companies. Pharmaceutical production costs are almost
50 percent lower in India than in western nations, while overall R&D costs are about one-eighth
and clinical trial expenses around one-tenth of western levels.
The Indian stock market may be dreading a possible recession but Indian pharma companies
seem unfazed by slowdown fears. Riding on better sales in the domestic and export markets,
Indian pharmaceutical industry is expected to continue with its good performance.
Today Indian pharmaceutical Industry can look forward to the years to come, with great
expectations. There are opportunities in expanding the range of generic products as more
molecule come off patent, outsourcing, and above all, in focusing into drug discovery as more
profits come from traditional plays. At the same time, the Indian Pharma Industry would have to
contend with several challenges particularly the
• Effects of new product patent
• Drug price control
• Regulatory reforms
• Infrastructure development
• Quality management and
• Conformance to global standards.
4.2 Growth
The Indian pharmaceutical market reached US$ 10.04 billion in size, with a value-wise growth
rate of 20.4 per cent over the previous year’s corresponding period on a Moving Annual Total
(MAT) basis for the 12 months ended July 2010.
Cipla maintained its leadership position in the domestic market with 5.27 per cent share,
followed by Ranbaxy. The highest growth in the domestic market was for Mankind Pharma,
11. which grew 37.2 per cent. Leading companies in the domestic market such as Sun Pharma (25.7
per cent), Abbott (25 per cent), Zydus Cadila (24.1 per cent), Alkem Laboratories (23.3 per cent),
Pfizer (23.6 per cent), GSK India (19 per cent), Piramal Healthcare (18.6 per cent) and Lupin
(18.8 per cent) had impressive growth during July 2010, shows the data.
The pharmaceuticals industry in India will grow by over 100 per cent over the next two years.
The pharmaceutical industry is currently growing at the rate of 12 per cent, but this will
accelerate soon. The sale of all types of medicines in the country stands at US$ 9.61 billion,
which is expected to reach around US$ 19.22 billion by 2012.
India's domestic pharmaceutical market is valued approximately at US$ 12 billion in 2010, and
has shown a strong growth of 21.3 per cent for the 12 months ending September 2010. It
estimates that over the next 10 years, the domestic market will grow to US$ 49 billion, at a
compounded annual growth rate (CAGR) of 15 per cent.
The formulations industry is expected to prosper parallel to the pharmaceutical industry. It is
expected that the domestic formulations market in India will grow at an annual rate of around 17
per cent in 2009-10, owing to increasing middle class population and rapid urbanisation.